Amicus Therapeutics Market Cap 2010-2022 | FOLD

Amicus Therapeutics market cap history and chart from 2010 to 2022. Market capitalization (or market value) is the most commonly used method of measuring the size of a publicly traded company and is calculated by multiplying the current stock price by the number of shares outstanding. Amicus Therapeutics market cap as of March 28, 2023 is $3.13B.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.132B $0.329B
Amicus Therapeutics, Inc. is a global patient-centric biotechnology company engaged in the discovery, development and commercialization of a diverse set of novel treatments for patients living with rare metabolic diseases.?The company has one marketed medicine in its portfolio named Galafold which is the first and the only approved oral precision medicine for patients living with Fabry disease, having amenable genetic variants. Migalastat is a potent orally available inhibitor of alpha-Gal A.?The drug was granted an accelerated approval by the FDA for treating adult patients with a confirmed diagnosis of Fabry disease and an amenable genetic variant. Galafold is the first and only oral therapy approved in the EU for the long-term treatment of adolescents with Fabry disease.?The lead pipeline candidate in the company's portfolio is AT-GAA, a differentiated biologic for Pompe disease. The company has one gene-therapy program in its pipeline CLN3, a type of Batten disease, being evaluated in a phase I/II study.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $143.172B 8.84
GSK (GSK) United Kingdom $75.535B 9.47
Bio-Rad Laboratories (BIO.B) United States $13.735B 32.61
QIAGEN (QGEN) Netherlands $10.564B 19.57
Ginkgo Bioworks Holdings (DNA) United States $2.549B 0.00
Arcus Biosciences (RCUS) United States $1.289B 0.00
Biohaven (BHVN) United States $0.959B 0.00
Emergent Biosolutions (EBS) United States $0.444B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.152B 0.00
Enzo Biochem (ENZ) United States $0.111B 0.00
SQZ Biotechnologies (SQZ) United States $0.019B 0.00
Gelesis Holdings (GLS) United States $0.013B 0.00